- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03376191
Apatinib in Advanced Non-squamous,NSCLC
Prospective, Multicenter, Non-intervention Clinical Trial of Apatinib in the Treatment of Advanced Non-squamous,Non-small Cell Lung Cancer
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
This is a multi-center, non-interventional clinical study. The number of patients that planned to be recruited is: from May 2017 to April 2019, the actual number of cases recruited into this study.
If the clinicians thought the patient is suitable to take apatinib treatment, and give the patient apatinib treatment, the patient can be recruited into this study. Clinicians chose the initial dose of apatinib according to the patient's physical condition. Besides the clinicians adjusted the dose according to the patient's tolerance during the medication. The dosage was demanded not higher than 750 milligram (mg) per day. The patients received apatinib continuously, 28 days for a period, until intolerance, no longer getting benefits or patient wanted stop.
During the course of the study, the researchers will not intervene the treatment of the patients, but only record the efficacy and adverse reactions.
Main evaluation criteria: PFS Secondary evaluation criteria: OS,DCR and ORR (according to RECIST1.1). Main safety indicators:AE, SAE (according to NCI CTCAE V4.0) and QOL scores (Quality of Life Questionnaire-lung cancer).
Tipo de estudio
Inscripción (Anticipado)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Beijing
-
Beijing, Beijing, Porcelana, 100142
- Reclutamiento
- Beijing Cancer Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Age: ≥ 18 years old;
- Histologically or cytologically confirmed, locally advanced or stage IV non-squamous, non-small cell lung cancer;
- Regardless of the past anti-tumor treatments (no limited to the number of past treatment lines), the doctors believe that apatinib can bring benefits to patients;
- The patient is voluntarily to join the study, and signed informed consent, good compliance, with follow-up.
Exclusion Criteria:
If any of the following criteria is met, the subject shall be excluded:
- Squamous cell carcinoma and/or small cell lung cancer patients;
- There are contraindications to apatinib (active bleeding, thrombosis, ulcers, intestinal perforation, intestinal obstruction, uncontrollable hypertension, grade III-IV cardiac insufficiency, major surgery within 30 days, severe liver and kidney dysfunction, etc.);
- Allergic to apatinib and / or its excipients;
- Pregnant or lactating women;
- According to the researcher's judgment, there are other situations that may increase the risk associated with participating in this study or the drug, which may lead to patients not being eligible for enrollment in the study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: Grupo
- Perspectivas temporales: Futuro
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
PFS (Progression-Free survival)
Periodo de tiempo: From the date Into this study (signed ICF) to tumor progression or death for any reason,whichever came first, assessed up to 36 months
|
From the date Into this study (signed ICF) to tumor progression or death for any reason.
|
From the date Into this study (signed ICF) to tumor progression or death for any reason,whichever came first, assessed up to 36 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
OS (Overall survival)
Periodo de tiempo: From the date Into this study (signed ICF) to death for any reason,assessed up to 60 months.
|
From the date Into this study (signed ICF) to death for any reason.
|
From the date Into this study (signed ICF) to death for any reason,assessed up to 60 months.
|
DCR (Disease control rate)
Periodo de tiempo: From the date Into this study (signed ICF) to tumor progression,assessed up to 36 months.
|
The rate of CR, PR plus SD
|
From the date Into this study (signed ICF) to tumor progression,assessed up to 36 months.
|
ORR (tasa de control objetivo)
Periodo de tiempo: Desde la fecha En este estudio (firmado ICF) hasta la progresión del tumor, evaluado hasta 36 meses.
|
La tasa de CR y PR
|
Desde la fecha En este estudio (firmado ICF) hasta la progresión del tumor, evaluado hasta 36 meses.
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
AE (Adverse events)
Periodo de tiempo: From the date Into this study (signed ICF) to 30 days after tumor progression, 30days after exit this research, or death,whichever came first, assessed up to 36 months.
|
AE is classified and graded by Common Terminology Criteria for Adverse Events (CTCAE) (version 4.0).
|
From the date Into this study (signed ICF) to 30 days after tumor progression, 30days after exit this research, or death,whichever came first, assessed up to 36 months.
|
SAE (Severe adverse events)
Periodo de tiempo: From the date Into this study (signed ICF) to 30 days after tumor progression, 30days after exit this research, or death,whichever came first, assessed up to 36 months.
|
SAE is classified and graded by Common Terminology Criteria for Adverse Events (CTCAE) (version 4.0).
|
From the date Into this study (signed ICF) to 30 days after tumor progression, 30days after exit this research, or death,whichever came first, assessed up to 36 months.
|
QOL scores
Periodo de tiempo: From the date Into this study (signed ICF) to tumor progression, exit this research, or death,whichever came first, assessed up to 36 months.
|
Quality of life scores
|
From the date Into this study (signed ICF) to tumor progression, exit this research, or death,whichever came first, assessed up to 36 months.
|
Colaboradores e Investigadores
Publicaciones y enlaces útiles
Publicaciones Generales
- Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, Wang Z, Wang Q, Ouyang X, Yang Y, Ba Y, Liang J, Lin X, Luo D, Zheng R, Wang X, Sun G, Wang L, Zheng L, Guo H, Wu J, Xu N, Yang J, Zhang H, Cheng Y, Wang N, Chen L, Fan Z, Sun P, Yu H. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol. 2016 May 1;34(13):1448-54. doi: 10.1200/JCO.2015.63.5995. Epub 2016 Feb 16.
- Didkowska J, Wojciechowska U, Manczuk M, Lobaszewski J. Lung cancer epidemiology: contemporary and future challenges worldwide. Ann Transl Med. 2016 Apr;4(8):150. doi: 10.21037/atm.2016.03.11.
- Hall RD, Le TM, Haggstrom DE, Gentzler RD. Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC). Transl Lung Cancer Res. 2015 Oct;4(5):515-23. doi: 10.3978/j.issn.2218-6751.2015.06.09.
- Zhang H. Apatinib for molecular targeted therapy in tumor. Drug Des Devel Ther. 2015 Nov 13;9:6075-81. doi: 10.2147/DDDT.S97235. eCollection 2015.
- Fontanella C, Ongaro E, Bolzonello S, Guardascione M, Fasola G, Aprile G. Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med. 2014 Dec;2(12):123. doi: 10.3978/j.issn.2305-5839.2014.08.14.
- Zhang L, Shi M, Huang C et al. A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens. J Clin Oncol 2012; 30: Abst 7548.
- Mi YJ, Liang YJ, Huang HB, Zhao HY, Wu CP, Wang F, Tao LY, Zhang CZ, Dai CL, Tiwari AK, Ma XX, To KK, Ambudkar SV, Chen ZS, Fu LW. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res. 2010 Oct 15;70(20):7981-91. doi: 10.1158/0008-5472.CAN-10-0111. Epub 2010 Sep 28.
- Ding L, Li QJ, You KY, Jiang ZM, Yao HR. The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature. Medicine (Baltimore). 2016 May;95(20):e3598. doi: 10.1097/MD.0000000000003598.
- Fan M, Zhang J, Wang Z, Wang B, Zhang Q, Zheng C, Li T, Ni C, Wu Z, Shao Z, Hu X. Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy. Breast Cancer Res Treat. 2014 Jan;143(1):141-51. doi: 10.1007/s10549-013-2793-6. Epub 2013 Dec 1.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades de las vías respiratorias
- Neoplasias
- Enfermedades pulmonares
- Neoplasias por sitio
- Neoplasias de las vías respiratorias
- Neoplasias torácicas
- Carcinoma Broncogénico
- Neoplasias Bronquiales
- Neoplasias Pulmonares
- Carcinoma de pulmón de células no pequeñas
- Mecanismos moleculares de acción farmacológica
- Inhibidores de enzimas
- Agentes antineoplásicos
- Inhibidores de la proteína quinasa
- Apatinib
Otros números de identificación del estudio
- APTN-NIS-NSCLC-BCH
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer de pulmón de células no pequeñas no escamoso
-
Adelphi Values LLCBlueprint Medicines CorporationTerminadoLeucemia de mastocitos (LCM) | Mastocitosis Sistémica Agresiva (ASM) | SM w Asoc Clonal Hema Non-mast Cell Linage Disease (SM-AHNMD) | Mastocitosis sistémica latente (MSS) | Mastocitosis Sistémica Indolente (ISM) Subgrupo ISM Completamente ReclutadoEstados Unidos
Ensayos clínicos sobre apatinib
-
Elevar TherapeuticsTerminadoCarcinoma quístico adenoideEstados Unidos, Corea, república de
-
Shanghai Jiao Tong University Affiliated Sixth...DesconocidoSarcoma de tejido blando
-
Peking University Cancer Hospital & InstituteReclutamiento
-
Tianjin Medical University Cancer Institute and...DesconocidoCáncer de pulmón de células pequeñasPorcelana
-
Peking Union Medical College HospitalTerminadoColangiocarcinoma | Neoplasia Hepatobiliar | Cáncer de vías biliares | BiomarcadorPorcelana
-
The First Affiliated Hospital of Zhengzhou UniversityReclutamientoCáncer de esófago por estadio AJCC V8Porcelana
-
Peking UniversityJiangsu HengRui Medicine Co., Ltd.Reclutamiento
-
The First Affiliated Hospital of Zhengzhou UniversityReclutamiento
-
Wuhan Union Hospital, ChinaRetiradoCáncer colonrectal | Quimioterapia | Angiogénesis
-
Peking Union Medical College HospitalTerminado